Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Resectable Hepatocellular Carcinoma: early-phase trial registry
2 of 5 indexed Resectable Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Resectable Hepatocellular Carcinoma: 5 US clinical trials tracked, 2 recruiting.
Resectable Hepatocellular Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition resectable-hepatocellular-carcinoma
OPEN 2 | RECR 40% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Resectable Hepatocellular Carcinoma lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Resectable Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Resectable Hepatocellular Carcinoma is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Resectable Hepatocellular Carcinoma research.
M.D. Anderson Cancer Center accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Resectable Hepatocellular Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 20 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Resectable Hepatocellular Carcinoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
M.D. Anderson Cancer Center
NCT02379377
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Jiping Wang, MD, PhD
NCT05701488
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
Mayo Clinic
NCT04856046
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
NCT04857684
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
NCT04721132
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Resectable Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Resectable Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Resectable Hepatocellular Carcinoma page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Resectable Hepatocellular Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Resectable Hepatocellular Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Resectable Hepatocellular Carcinoma condition card totals 5 registered trials; most-linked intervention Stereotactic Beam Radiation Therapy (SBRT); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.